PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth 1.1-1.25x TRVN's 9.21%. Bill Ackman would demand evidence of superior returns.
23.98%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
15.26%
Operating expenses growth above 1.5x TRVN's 6.25%. Michael Burry would check for inefficiency.
15.26%
Total costs growth above 1.5x TRVN's 6.25%. Michael Burry would check for inefficiency.
-36.68%
Both companies reducing interest expense. Martin Whitman would check industry trends.
7.46%
D&A growth 1.1-1.25x TRVN's 6.10%. Bill Ackman would demand investment justification.
-50.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Both companies reducing tax expense. Martin Whitman would check patterns.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-43.14%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.01%
Share count reduction below 50% of TRVN's 1.61%. Michael Burry would check for concerns.
5.01%
Diluted share reduction below 50% of TRVN's 1.61%. Michael Burry would check for concerns.